The Hers application organized a smartphone in New York on February 12, 2025.
Gabby Jones | Bloomberg | Getty images
Actions of Hims and his health 9% fell in extended operations on Monday after the Telesalud company reported results of the second quarter that lost the income expectations of Wall Street.
This is how the company was based on the estimates of the average analysts compiled by LSE:
- Profit per action: 17 tight cents compared to 15 expected cents
- Revenue: $ 544.8 million compared to $ 552 million
Income at Hims & Hers increased 73% in the second quarter of $ 315.6 million during the same period last year, according to a statement. Hims & Hers reported a net income of $ 42.5 million, or 17 cents per share, compared to $ 13.3 million, or 6 cents per share, during the same period of the previous year.
For his third quarter, Hims & Hers said he hoped to inform the income between $ 570 million and $ 590 million, while analysts waited $ 583 million. The company said its adjusted profits before interest, taxes, depreciation and amortization, or Ebitda, will be between the range of $ 60 million and $ 70 million for the quarter. Analysts surveyed by Streetaccount waited $ 77.1 million.
HIMS & HERS has faced a controversy in recent months about its continuous sale of LPG-1 compounds, which are cheaper and not approved versions of the successful diabetes and drugs to lose weight. Composite medicines can be produced by mass when brand name treatments are scarcity, but the United States drug and food administration announced in February that the current supply problems had been solved.
Some Telesalud companies, including Hims and Hers, have continued to offer compound medications. It is legal that patients access personalized doses of imitations in unique cases, as if they are allergic to an ingredient in a brand product, for example. HIMS & Hers has said that consumers can still access custom doses through their site if clinically applicable.
In June, Higs & Hers the actions fell more than 30% after a short -term collaboration with Novo Nordisk He crumbled. The drug manufacturer said that Hims & Hers “did not adhere to the law that prohibits mass sales of composite drugs” under the “false appearance” of customization.
Hims & Hers reported an adjusted Ebitda of $ 82 million for its second quarter, compared to $ 39.3 million last year and above the $ 73 million expected by Streetacount.
HIMS & HERS will organize its quarterly call with investors at 5 PM et.
YTD HIMS graphic and your health.
– Annika Kim Constantino of CNBC contributed to this report.
